LOX and ovarian cancer: To determine if this observed limited invasive capacity resulted from decreased extracellular matrix remodeling activity, as a proof-of-concept we next determined MMP2 and LOX protein expression in drug-treated spheroids (Figures 8B) since these proteins are associated with ovarian cancers’ invasive capacity (47–49).